- $1.76bn
- $1.54bn
- $7.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.27 | ||
| Price to Tang. Book | 8.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 238.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.17% | ||
| Return on Equity | -40.59% | ||
| Operating Margin | -1032.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 10.31 | 13.67 | 7.46 | 7.4 | 1.5 | 1.71 | -10.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). It uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- August 11th, 2023
- Public Since
- June 18th, 2021
- No. of Shareholders
- 38
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 63,006,294
- Address
- 10975 North Torrey Pines Road, LA JOLLA, 92037
- Web
- https://ambrx.com/
- Phone
- +1 8588752400
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AMAM
Full Year 2023 Ambrx Biopharma Inc Earnings Release
Similar to AMAM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Ambrx Biopharma share price?
As of Today at 18:02 UTC, shares in Ambrx Biopharma are trading at $27.98. This share price information is delayed by 15 minutes.
How has the Ambrx Biopharma share price performed this year?
Shares in Ambrx Biopharma last closed at $27.98 and the price had moved by +311.47% over the past 365 days. In terms of relative price strength the Ambrx Biopharma share price has outperformed the S&P500 Index by +224.05% over the past year.
What are the analyst and broker recommendations for Ambrx Biopharma?
The overall consensus recommendation for Ambrx Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ambrx Biopharma dividend yield?
Ambrx Biopharma does not currently pay a dividend.
Does Ambrx Biopharma pay a dividend?
Ambrx Biopharma does not currently pay a dividend.
When does Ambrx Biopharma next pay dividends?
Ambrx Biopharma does not currently pay a dividend.
How do I buy Ambrx Biopharma shares?
To buy shares in Ambrx Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ambrx Biopharma?
As of the previous close price of $27.98, shares in Ambrx Biopharma had a market capitalisation of $1.76bn.
Where are Ambrx Biopharma shares listed?
Here are the trading details for Ambrx Biopharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMAM
What kind of share is Ambrx Biopharma?
Based on an overall assessment of its quality, value and momentum Ambrx Biopharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ambrx Biopharma share price forecast for 2024?
The analyst consensus target price for shares in Ambrx Biopharma is $28.50. That is 1.86% above the last closing price of $27.98.
Analysts covering Ambrx Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.37 for the next financial year.
What is the trend in the Ambrx Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ambrx Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +73.09%.
As of the last closing price of $27.98, shares in Ambrx Biopharma were trading +77.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ambrx Biopharma PE Ratio?
The Ambrx Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $27.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ambrx Biopharma?
We do not have data on Ambrx Biopharma's directors